Ines S. M.
- Country
- Croatia
- Department
- Dermatology department
Research Overview
- Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Trial Evaluating Lutikizumab Efficacy and Safety in Moderate to Severe Hidradenitis Suppurativa
- A Multicenter, Double-Blind, Randomized Withdrawal Study of Subcutaneous Secukinumab for Long-Term Efficacy and Safety in Moderate to Severe Hidradenitis Suppurativa
Data & Insights
Has run more than one trial at 22 of 120 partner sites.
Specializations
Inflammatory Skin Conditions
This investigator specializes in the treatment and management of hidradenitis suppurativa, focusing particularly on advanced therapeutic approaches for moderate to severe cases.
- Chronic inflammatory skin disorders
- Treatment-resistant conditions
- Long-term disease management
Expertise extends to evaluating novel biological therapies for inflammatory skin conditions.
Therapeutic Innovation
The investigator explores innovative biological treatments including targeted therapies for chronic inflammatory conditions.
- Biological therapy assessment
- Treatment response evaluation
- Long-term efficacy studies
Special focus on comparing continuous versus interrupted treatment protocols in chronic conditions.
Patient Care Optimization
Dedicated to advancing treatment protocols for both adult and adolescent patients with inflammatory skin disorders.
- Age-specific treatment approaches
- Dosing optimization strategies
- Safety monitoring protocols
Focuses on developing effective long-term management strategies for chronic skin conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.